New York, USA – October 15, 2020 – IntegrateRNA, the division of Creative Biogene, is dedicated to providing the most comprehensive range of specialized RNA products and services to genetic researchers for basic research, drug development, and clinical research, recently it unleashed a comprehensive lncRNA service from strategy design to final stable cell line in order to target gene expression and treating many terrible human diseases.
lncRNA is expressed differently in various types of cancers, including leukemia, breast cancer, hepatocellular carcinoma, colon cancer and prostate cancer. Moreover, lncRNA seems to be loosely regulated in other diseases (such as cardiovascular diseases, neurological diseases, and immune-mediated diseases). Although the understanding of the functional role of lncRNAs has grown rapidly, the field is still in its infancy, and their role in human diseases still needs further exploration. The lncRNA expert team can provide complete and innovative solutions to help customers solve the problems encountered in the research process.
IntegrateRNA has successfully embedded the CRISPR/Cas9 system into RNA research, and introduced a customized lncRNA knockout service through the CRISPR/Cas9 system, which can help researchers construct lncRNA libraries and knock out lncRNA genes. IntegrateRNA has many years of RNA research experience, including various RNA discovery, functional research, bioinformatics research, gene editing, and provides novel strategies to improve efficiency and success rate.
In addition, based on the experience in the lncRNA field, IntegrateRNA provides customers with a comprehensive lncRNA pull-down service, from the initial experimental design to the final identification of interacting molecules. Experienced scientists and advanced technology can provide consistent and high-quality data in a cost-effective manner. Customers only need to provide RNA sequences or plasmids (species) constructed from RNA sequences, and cell samples of the same species. Integraterna will provide plasmid construction and sequencing reports of bacterial solutions containing target genes, in vitro transcription template sensor and antisense primers and template electrophoresis images, RNA pull-down protein SDS-PAGE silver staining and mass spectrometry reports.
In order to integrate rapid scientific progress and new data to promote lncRNA research, RNA Science has developed an lncRNA array service for humans and rodents to provide the latest, more comprehensive and reliable determination method of lncRNA in samples used in biological sciences. This is also a practical long-term non-coding RNA analysis platform with high sensitivity and specificity for medical research. Integraterna provides a complete lncRNA array analysis service from RNA sample preparation to data analysis. The step-by-step quality control is designed to ensure you get the most reliable results. Integrrna provides the most sensitive and best technology for lncRNA analysis superior to RNA-seq, and selects a comprehensive and powerful collection of full-length lncRNAs from all major latest databases and landmark publications. Furthermore, systematic lncRNA annotation and analysis combine the progress of lncRNA research, including genomic background, epigenome, integrity, subcellular localization and miRNA recognition.
“IntegrateRNA is a biotechnology company with experienced scientists and advanced technology, committed to providing the most comprehensive and professional services for all types of RNA through strict quality control and advanced bioinformatics analysis,” said Marcia Brady, she also added, “we can help you obtain comprehensive lncRNA bioinformatics data and publication quality graphics at one time.”
IntegrateRNA, as the division of Creative Biogene that holds a leading position in providing complete solutions for RNA research, has years of experience in next-generation sequencing and develops microarray platforms that enable researchers to explore the world of RNA on an unprecedented scale, and mapping all RNAs involved in cell life programs, human diseases, and drug discovery.